A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation

Science Translational Medicine

Volumn 1, Issue 1, 2009, Pages

  Gesty Palmer, Diane ^a,b   Flannery, Pat ^a   Yuan, Ling ^a   Corsino, Leonor ^a   Spurney, Robert ^a   Lefkowitz, Robert J ^a   Luttrell, Louis M ^c,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PARATHYROID HORMONE RECEPTOR 1; RETINA S ANTIGEN;

ANIMAL; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; DRUG EFFECT; DRUG POTENTIATION; MALE; METABOLISM; MOUSE; MOUSE MUTANT; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; BONE DENSITY; BONE DEVELOPMENT; GTP-BINDING PROTEINS; MALE; MICE; MICE, KNOCKOUT; RECEPTOR, PARATHYROID HORMONE, TYPE 1; SIGNAL TRANSDUCTION;

EID: 73949084919     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000071     Document Type: Article

References (41)

1. L. Qin, L. J. Raggatt, N. C. Partridge, Parathyroid hormone: A double-edged sword for bone metabolism. Trends Endocrinol. Metab. 15, 60-65 (2004).
2. J. M. Hock, I. Gera, Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res. 7, 65-72 (1992).
3. H. Dobnig, R. T. Turner, Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136, 3632-3638 (1995).
4. M. Girotra, M. R. Rubin, J. P. Bilezikian, The use of parathyroid hormone in the treatment of osteoporosis. Rev. Endocr. Metab. Disord. 7, 113-121 (2006).
5. A. J. Koh, C. A. Beecher, T. J. Rosol, L. K. McCauley, 3′,5′-Cyclic adenosine monophosphate activation in osteoblastic cells: Effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140, 3154-3162 (1999).
6. T. Ishizuya, S. Yokose, M. Hori, T. Noda, T. Suda, S. Yoshiki, A. Yamaguchi, Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99, 2961-2970 (1997).
7. S. Hilliker, J. E. Wergedal, H. E. Gruber, P. Bettica, D. J. Baylink, Truncation of the amino terminus of PTH alters its anabolic activity on bone in vivo. Bone 19, 469-477 (1996).
8. F. R. Bringhurst, H. Juppner, J. Guo, P. Urena, J. T. Potts Jr., H. M. Kronenberg, A. B. Abou-Samra, G. V. Segre, Cloned, stably expressed parathyroid hormone (PTH)/PTH-related peptide receptors activate multiple messenger signals and biological responses in LLC-PK1 kidney cells. Endocrinology 132, 2090-2098 (1993).
9. J. T. Swarthout, R. C. D'Alonzo, N. Selvamurugan, N. C. Partridge, Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282, 1-17 (2002).
10. J. A. Cole, Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells. Endocrinology 140, 5771-5779 (1999).
11. D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C. D. Nelson, S. Wang, A. E. Eckhardt, C. L. Cowan, R. F. Spurney, L. M. Luttrell, R. J. Lefkowitz, Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856-10864 (2006).
12. M. H. Verheijen, L. H. Defize, Parathyroid hormone activates mitogen-activated protein kinase via a cAMP-mediated pathway independent of Ras. J. Biol. Chem. 272, 3423-3429 (1997).
13. L. M. Luttrell, R. J. Lefkowitz, The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J. Cell Sci. 115, 455-465 (2002).
14. N. J. Freedman, R. J. Lefkowitz, Desensitization of G protein-coupled receptors. Recent Prog. Horm. Res. 51, 319-351; discussion 352-353 (1996).
15. K. L. Pierce, R. J. Lefkowitz, Classical and new roles of β-arrestins in the regulation of G-protein-coupled receptors. Nat. Rev. Neurosci. 2, 727-733 (2001).
16. 2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661 (1999).
17. S. K. Shenoy, R. J. Lefkowitz, Seven-transmembrane receptor signaling through β-arrestin. Sci. STKE 2005, cm10 (2005).
18. R. J. Lefkowitz, S. K. Shenoy, Transduction of receptor signals by β-arrestins. Science 308, 512-517 (2005).
19. S. M. DeWire, S. Ahn, R. J. Lefkowitz, S. K. Shenoy, β-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
20. P. H. McDonald, C. W. Chow, W. E. Miller, S. A. Laporte, M. E. Field, F. T. Lin, R. J. Davis, R. J. Lefkowitz, β-arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574-1577 (2000).
21. K. A. DeFea, J. Zalevsky, M. S. Thoma, O. Dery, R. D. Mullins, N. W. Bunnett, β-arrestindependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148, 1267-1281 (2000).
22. L. M. Luttrell, F. L. Roudabush, E. W. Choy, W. E. Miller, M. E. Field, K. L. Pierce, R. J. Lefkowitz, Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci. U.S.A. 98, 2449-2454 (2001).
23. S. L. Ferrari, V. Behar, M. Chorev, M. Rosenblatt, A. Bisello, Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves β-arrestin2. Real-time monitoring by fluorescence microscopy. J. Biol. Chem. 274, 29968-29975 (1999).
24. J. P. Vilardaga, C. Krasel, S. Chauvin, T. Bambino, M. J. Lohse, R. A. Nissenson, Internalization determinants of the parathyroid hormone receptor differentially regulate β-arrestin/receptor association. J. Biol. Chem. 277, 8121-8129 (2002).
25. M. L. Bouxsein, D. D. Pierroz, V. Glatt, D. S. Goddard, F. Cavat, R. Rizzoli, S. L. Ferrari, β-Arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bone Miner. Res. 20, 635-643 (2005).
26. S. L. Ferrari, D. D. Pierroz, V. Glatt, D. S. Goddard, E. N. Bianchi, F. T. Lin, D. Manen, M. L. Bouxsein, Bone response to intermittent parathyroid hormone is altered in mice null for β-arrestin2. Endocrinology 146, 1854-1862 (2005).
27. T. Kenakin, Inverse, protean, and ligand-selective agonism: Matters of receptor conformation. FASEB J. 15, 598-611 (2001).
28. J. A. Brzostowski, A. R. Kimmel, Signaling at zero G: G-protein-independent functions for 7-TM receptors. Trends Biochem. Sci. 26, 291-297 (2001).
29. T. Kenakin, Functional selectivity through protean and biased agonism: Who steers the ship? Mol. Pharmacol. 72, 1393-1401 (2007).
30. D. Gesty-Palmer, L. M. Luttrell, Heptahelical terpsichory. Who calls the tune? J. Recept. Signal Transduct. Res. 28, 39-58 (2008).
31. J. D. Violin, R. J. Lefkowitz, β-arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28, 416-422 (2007).
32. T. J. Gardella, M. D. Luck, G. S. Jensen, E. Schipani, J. T. Potts Jr., H. Jüppner, Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137, 3936-3941 (1996).
33. L. M. Bohn, R. J. Lefkowitz, R. R. Gainetdinov, K. Peppel, M. G. Caron, F. T. Lin, Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495-2498 (1999).
34. L. C. Hofbauer, M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292, 490-495 (2004).
35. M. Pi, R. H. Oakley, D. Gesty-Palmer, R. D. Cruickshank, R. F. Spurney, L. M. Luttrell, L. D. Quarles, β-arrestin- and G protein receptor kinase-mediated calcium-sensing receptor desensitization. Mol. Endocrinol. 19, 1078-1087 (2005).
36. S. C. Garner, M. Pi, Q. Tu, L. D. Quarles, Rickets in cation-sensing receptor-deficient mice: An unexpected skeletal phenotype. Endocrinology 142, 3996-4005 (2001).
37. i. Demonstration in a reconstituted system. J. Biol. Chem. 277, 31249-31256 (2002).
38. 1-adrenergic receptor determine the selectivity of coupling to phosphatidylinositol hydrolysis. J. Biol. Chem. 267, 1633-1639 (1992).
39. L. Wang, S. Liu, L. D. Quarles, R. F. Spurney, Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Am. J. Physiol. Endocrinol. Metab. 288, E826-E834 (2005).
40. R. F. Spurney, P. J. Flannery, S. C. Garner, K. Athirakul, S. Liu, F. Guilak, L. D. Quarles, Anabolic effects of a G protein-coupled receptor kinase inhibitor expressed in osteoblasts. J. Clin. Invest. 109, 1361-1371 (2002).
41. A. M. Parfitt, M. K. Drezner, F. H. Glorieux, J. A. Kanis, H. Malluche, P. J. Meunier, S. M. Ott, R. R. Recker, Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2, 595-610 (1987).